Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 19th Euro Congress on Cancer Science and Therapy Lisbon, Portugal.

Day 2 :

OMICS International Cancer Science 2017 International Conference Keynote Speaker Isaura Meza photo

In the tumor inflammatory microenvironment, interleukin-1β (IL-1β) has been associated with tumor development, invasiveness, metastasis and initiation of the epithelial to mesenchymal transition (EMT). Using a model of breast cancer non-invasive cells, we have recently demonstrated that IL-1β triggers the activation of a signaling pattern, not previously described, named as IL-1β/IL-1RI/β-catenin that induces accumulation of β-catenin in the nucleus and GSK1 inactivation by AKT phosphorylation. Translocation of β-catenin to the nucleus and formation of the TCF/Lef/β-catenin complex causes sequential expression of genes that leads to up-regulation of cell proliferation, migration and invasion. By the activation of these processes, the IL-1β-stimulated cells enter the transition program, from a non-invading to an invading phenotype, known as EMT. Initial results on a selected MCF-7 cell clone (6D) highly sensitive to IL-1β showed that IL-1β up-regulated SNAIL, c-MYC and MMP2, genes involved in replication and invasion. Subsequent RNA-seq showed direct correlation between upregulation of cell survival and drug resistance genes such as BIRC3, CDKN1A, TP63 and BCL2. Our results with this 6D cell model, in which EMT has been induced by IL-1β, showed that methylation of the ESR1 promoter occurred as consequence of the up-regulation of TWIST1 through the cytokine activated pathway, leading to decreased levels of the oestrogen receptor ERα, as observed in aggressive breast cancer tumors classified as triple negative. We hope that our results showing some of the mechanisms by which an inflammatory environment influences malignancy will draw attention to this aspect of cancer pathology and the possibility for using new therapeutic schemes in its treatment.


Isaura Meza graduated from the University of California, Berkeley and has always been interested in cell motility mechanisms. She has done her Post-doctoral studiesfrom the University of Geneva. She works as a Professor at CINVESTAV in Mexico City.

Keynote Forum

Maru Barrera

Dept. of Psychology and Division of Hematology/ Oncology, Canada

Keynote: Why is early psychosocial screening important in pediatric cancer?

Time : 10.15-10.55

OMICS International Cancer Science 2017 International Conference Keynote Speaker Maru Barrera photo

Maru Barrera completed her MA from the University of North Carolina in USA and PhD at McMaster University in Canada. She is a Psychologist and Senior Associate Scientist in Hematology/Oncology and Department of Psychology at Hospital for Sick Children, Toronto, ON; and an Associate Professor at University of Toronto in Medical Sciences and Education. Her research includes: Development and RCT assessment of group intervention programs for children treated for brain tumors and for siblings and investigating early psychosocial screening for improved psychosocial outcomes. She has published over 115 scientific articles in high impact scientific journals.


Diagnosis of childhood cancer and its aggressive treatment can have a devastating psychosocial impact on the whole family. The child undergoing cancer treatment encounters a host of negative experiences which may result in fear, anxiety and pain and severe psychosocial distress. Parents of children with cancer also face devastating situations and disruption of daily life that can result in severe psychosocial distress and symptoms of anxiety and depression. Parents’ behavior and anxiety during their child’s medical procedures predicts their child’s distress reaction and child and parent adjustment after diagnosis is the best predictor of adjustment two years later. Although the majority of families adjust well over time significant number experience long-term psychosocial difficulties. In this presentation, the author will describe some of his research evaluating the impact of providing early psychosocial risk information to the treating team, based on the psychosocial assessment tool (PAT) completed by parents shortly after diagnosis. Compared to a randomized control group (no information to treating team),results will describe reduced distress and improved quality of life (QOL) in the child with cancer and his/her parents and siblings six months from baseline. Additional findings from a more recent and larger study will also be presented describing mental health outcomes in the child with cancer, one parent and one sibling. Implications for patient care will be discussed.